Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300714 | 0.92 | CYP19A1 (0.45) | ABCB1ABCG2CYP19A1ALDH1A1TSHR | |
| SCHEMBL687916 | 0.87 | NR1H4 (0.50) | NR1H4ABCB1ABCG2CDK4CCND1 | |
| SCHEMBL29880554 | 0.87 | NR1H4 (0.50) | NR1H4ABCB1ABCG2CDK4CCND1 | |
| SCHEMBL328164 | 0.86 | NR1H4 (0.49) | NR1H4ABCB1ABCG2CDK4CCND1 | |
| SCHEMBL4300281 | 0.82 | HSD17B10 (0.47) | ALDH1A1TSHR | |
| SCHEMBL4302795 | 0.79 | ABCG2 (0.43) | NR1H4ABCB1ABCG2 | |
| SCHEMBL274449 | 0.79 | NR1H4 (0.67) | NR1H4ALDH1A1 | |
| SCHEMBL273514 | 0.79 | NR1H4 (0.67) | NR1H4ALDH1A1 | |
| SCHEMBL275134 | 0.79 | NR1H4 (0.67) | NR1H4ALDH1A1 | |
| SCHEMBL5733404 | 0.78 | NR1H4 (0.49) | NR1H4ABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595311-B2 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | EXELIXIS, INC. (US) | 2009-09-29 | — | — | US | claimed |
| CN-110404073-B | Methods and pharmaceutical compositions for treating hepatitis B virus infection | 国家医疗保健研究所 | 2022-08-16 | — | — | CN | disclosed |